Growth hormone is not safe for children with renal transplants

Area of Science:

• Pediatric Nephrology
• Endocrinology
• Transplantation Immunology

Background:

• Children with renal failure often experience growth failure, persisting even after kidney transplantation.
• Growth hormone (GH) is considered for post-transplant growth issues, but its safety is uncertain.
• Concerns exist regarding GH's potential negative impact on renal function and graft survival.

Purpose of the Study:

• To evaluate the safety and efficacy of growth hormone (GH) administration in pediatric kidney transplant recipients.
• To investigate the potential risks associated with GH therapy, including effects on renal function and immune response.

Main Methods:

• Review of clinical observations and theoretical considerations regarding GH use post-transplantation.
• Analysis of existing studies examining GH therapy in renal injury and transplantation models.
• Assessment of GH's known effects on immune modulation and kidney pathology.

Main Results:

• Studies indicate a potential for accelerated decline in renal function following GH therapy initiation.
• GH may influence the immune response, potentially increasing the risk of graft rejection.
• Experimental data suggest GH can exacerbate glomerular sclerosis and reduce function in injured kidneys.

Conclusions:

• Growth hormone (GH) administration post-kidney transplantation poses significant safety concerns.
• Potential risks include accelerated renal function decline, heightened immune rejection, and kidney damage.
• GH should not be used in pediatric kidney transplant recipients until prospective clinical trials confirm its safety.